Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial.

TitleMyeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial.
Publication TypeJournal Article
Year of Publication2021
AuthorsScott, BL, Pasquini, MC, Fei, M, Fraser, R, Wu, J, Devine, SM, Porter, DL, Maziarz, RT, Warlick, E, Fernandez, HF, Soiffer, RJ, Alyea, E, Hamadani, M, Bashey, A, Giralt, S, Geller, NL, Leifer, E, Hourigan, CS, Gui, G, Mendizabal, A, Horowitz, MM, H Deeg, J, Horwitz, ME
JournalTransplant Cell Ther
Volume27
Issue6
Pagination483.e1-483.e6
Date Published2021 06
ISSN2666-6367
KeywordsAdolescent, Adult, Aged, Diterpenes, Follow-Up Studies, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Middle Aged, Myelodysplastic Syndromes, Prospective Studies, Transplantation Conditioning, Transplantation, Homologous, Young Adult
Abstract

Several prospective randomized trials comparing conditioning intensity before allogeneic hematopoietic cell transplantation (HCT) have been performed, with conflicting results. Although reduced-intensity conditioning (RIC) leads to lower treatment-related mortality (TRM), this is offset by higher rates of relapse. Long-term follow-up of randomized comparative trials are limited. Here we present long-term follow-up of a randomized comparison of myeloablative conditioning (MAC) compared with RIC before HCT for acute myelogenous leukemia (AML) or myelodysplasia (MDS). Long-term comparative analyses of overall survival, relapse, and relapse-free survival were performed. Patients age 18 to 65 years with

DOI10.1016/j.jtct.2021.02.031
Alternate JournalTransplant Cell Ther
PubMed ID33775615
PubMed Central IDPMC8217373
Grant ListU10 HL069294 / HL / NHLBI NIH HHS / United States
UG1 HL069290 / HL / NHLBI NIH HHS / United States
U01 HL069274 / HL / NHLBI NIH HHS / United States
U10 HL069274 / HL / NHLBI NIH HHS / United States
UG1 HL108987 / HL / NHLBI NIH HHS / United States
P30 CA008748 / CA / NCI NIH HHS / United States
UG1 HL069274 / HL / NHLBI NIH HHS / United States
UG1 HL138658 / HL / NHLBI NIH HHS / United States
U24 CA076518 / CA / NCI NIH HHS / United States
U24 HL138660 / HL / NHLBI NIH HHS / United States